Request Processed
Your registration request has been processed. We will contact you soon.
Register
First name
Last name
Email
Company
Toggle navigation
Toggle navigation
Login
Register
About
Contact Us
1
2
3
4
5
6
Next ›
Last »
Prevision Policy Clips | Pfizer Will Present On Three Vaccine Candidates During February ACIP Meeting
February 21, 2023
“The Will” Vs. “The Wait”: CBER’s Marks, OTAT’s Bryan Give Differing Views Of Accelerated Approval For Gene Therapies
February 17, 2023
Emergent’s Narcan Nasal Spray Unanimously Supported For OTC Use; Set To Be First Nonprescription Opioid Reversal Agent – And First-Of-Its Kind FDA-Initiated Public Health Switch
February 17, 2023
Prevision Policy Clips | FDA Office Of Oncologic Diseases Deputy Director Slot Vacant After Julia Beaver Departs
February 17, 2023
FDA Gene Therapy Reorg: Industry Should Expect “A Year Or Two” For Staffing To Catch Up With Demand; Policy Plans Include “Platform,” Efforts Inspired By “Warp Speed,” RTOR And Orbis
February 16, 2023
FDA’s Califf Calls For Return To Large, Simple Trials Without “Useless Stuff” That Slows Development; Praises OCE’s “Project Pragmatica”
February 16, 2023
CMMI Drug Pricing Models: $2 Generics Ready To Go; Centralized Gene Therapy Contracts May Support SCD Launches; Can CMS Help Accelerated Approval?
February 16, 2023
Prevision Policy Clips | Moderna To Testify At Senate HELP Committee On COVID Vaccine Pricing Plans
February 16, 2023
FDA Advisory Committees Moving To In-Person Meetings: Califf Envisions Earlier, Big-Picture Topics For Discussion, Less “Gladiator”-Type Approval Votes
February 16, 2023
Prevision Policy Clips | Drug Pricing Demos Announced By HHS—But Implementation Timeline And Details Are Still TBD
February 15, 2023
CMS Considering New Approaches For Gene Therapy In Medicaid, But Not ASP Or “Protected Class” Changes; COO Blum Calls For Data On IRA Impact On Innovation
February 14, 2023
Prevision Policy Clips | CBER Listening Session On Cell/Gene Therapy Data Collection From RWE/Registries
February 14, 2023
Prevision Policy Clips | CBER Working On Warp Speed For Rare Diseases, Director Peter Marks
February 13, 2023
Project Orbis Update: 71 Orbis Approvals and Counting Since Program Began in 2019
February 12, 2023
GSK Jemperli Accelerated Approval In Rectal Cancer Is Possible With Tweaks To Proposed Plan, FDA Committee Says; Model For AA Plans?
February 10, 2023
USPTO/FDA Coordination On Patents: First Practical, Politically Palatable Lesson May Be For PTO To Adopt FDA Processes For Soliciting Patient Perspective
February 10, 2023
Medicare Inflation Rebate Implementation Plan Unveiled: Manufacturers Would Have 10 Days To Check Invoices For Errors Under Proposed Policy; CMS Expects First Invoices In 2025
February 10, 2023
Prevision Policy Clips | FDA Commissioner Robert Califf To Keynote Biopharma Congress On February 13; FDORA, Impacts Of The IRA
February 10, 2023
Pharma Patent/Competition Bills Return In Senate; Bipartisan Talks Continue On Scope Of FTC Authorities
February 9, 2023
FDA/Sponsor Communication To Be Subject Of House E&C Hearings; Advisory Committees, Inspections Among Other Questions For Califf During COVID Hearing
February 9, 2023
Prevision Policy Clips | FDA COVID “Direct-To-Final” Guidance Clean-Up: Agency Withdraws Propofol Re-Packaging Policy
February 9, 2023
Accelerated Approval For Gene Therapies: OTAT Town Hall Suggests Pathway Viable In Slowly Progressive Disease With Clear Natural History
February 8, 2023
“Project Pause”? FDA Cancer Center Launches Fewer New Projects In 2022 To Allow Time To Advance Existing Work
February 8, 2023
Prevision Policy Clips | President Biden Takes IRA Victory Lap During State Of The Union
February 8, 2023
GSK’s Jemperli ODAC May Be Public Test Case For Accelerated Approval Development Meetings; Committee To Discuss Novel Endpoints At IND Stage
February 7, 2023
1
2
3
4
5
6
Next ›
Last »